John McHutchison - Gilead Sciences Executive Vice President - Clinical Research

GILD Stock  USD 73.25  0.24  0.33%   

President

Dr. John G. McHutchison, M.D. is no longer Chief Scientific Officer and Head of Research and Development of the Company, effective August 2, 2019. Dr. McHutchison was appointed Chief Scientific Officer in March 2018. Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and CoDirector of the Duke Clinical and Translational Science Award. Prior to his positions at Duke, Dr. McHutchison spent nearly 10 years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. In June 2018, Dr. McHutchison was appointed an Officer of the Order of Australia in recognition of his distinguished service to medical research in gastroenterology and hepatology. Dr. McHutchison has undergraduate degrees in medicine and surgery from the University of Melbourne in Australia and completed his residency in internal medicine and fellowship in gastroenterology at the Royal Melbourne Hospital. He is a member of the Royal Australasian College of Physicians. since 2018.
Age 60
Tenure 6 years
Address 333 Lakeside Drive, Foster City, CA, United States, 94404
Phone650 574 3000
Webhttps://www.gilead.com

Gilead Sciences Management Efficiency

The company has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2554 %, meaning that it created $0.2554 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.19. The current year's Return On Assets is expected to grow to 0.1. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.9 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.
The company currently holds 24.99 B in liabilities with Debt to Equity (D/E) ratio of 1.3, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 1.4, which is within standard range for the sector. Debt can assist Gilead Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Gilead Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Gilead Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Gilead to invest in growth at high rates of return. When we think about Gilead Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Ryutaro IchimuraNetEase
N/A
James ClackPACCAR Inc
52
Jason SkoogPACCAR Inc
46
Samuel MeansPACCAR Inc
46
Michael DozierPACCAR Inc
58
Preston FeightPACCAR Inc
56
Harrie SchippersPACCAR Inc
61
Darrin SiverPACCAR Inc
57
Alma LeyPACCAR Inc
52
Douglas GrandstaffPACCAR Inc
57
Lily LeyPACCAR Inc
58
Gary MoorePACCAR Inc
62
Jack LeVierPACCAR Inc
58
Marco DavilaPACCAR Inc
59
David DanforthPACCAR Inc
57
Michael BarkleyPACCAR Inc
69
David AndersonPACCAR Inc
61
Brendan RileyGreenPower Motor
53
James LaneMarine Products
71
Todd HubbardPACCAR Inc
55
Benjamin PalmerMarine Products
60
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 14400 people. Gilead Sciences (GILD) is traded on NASDAQ Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA, United States, 94404 and employs 18,000 people. Gilead Sciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Gilead Sciences Leadership Team

Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kathleen Watson, Executive Vice President - Human Resources
John McHutchison, Executive Vice President - Clinical Research
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations
John Martin, Chairman and CEO
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Michael Quigley, VP Biology
Linda Higgins, Innovation Research
Gayle Wilson, Independent Director
Daniel ODay, Chairman of the Board, CEO
Jacqueline Barton, Director
Brett Pletcher, Executive VP and General Counsel
William Lee, Executive Vice President - Research
Deborah Telman, General Affairs
John Madigan, Independent Director
Martin Silverstein, Executive Vice President - Strategy
Kevin Lofton, Independent Director
Jacquie CFA, Vice Relations
Paul Carter, Executive Vice President - Commercial Operations
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections
Flavius MD, Executive Research
Carla Hills, Independent Director
John Cogan, Lead Independent Director
Sandra Patterson, Corporate VP
John Milligan, Pres and COO
Nicholas Moore, Independent Director
James Meyers, Executive Vice President - Worldwide Commercial Operations
Katie Watson, Executive Vice President of Human Resources
Kelly Kramer, Director
Johanna Mercier, Chief Commercial Officer
Jyoti Mehra, Executive Vice President of Human Resources
Laura Hamill, Executive Vice President - Worldwide Commercial Operations
Robin Washington, CFO and Executive VP
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD
Per WoldOlsen, Independent Director
Harish Manwani, Director
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing
Kevin Young, COO
Etienne Davignon, Independent Director
Richard Whitley, Independent Director
Diane Wilfong, Corp VP
Rudolf Ertl, Canada, Australia

Gilead Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Gilead Sciences Investors Sentiment

The influence of Gilead Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Gilead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Gilead Sciences' public news can be used to forecast risks associated with an investment in Gilead. The trend in average sentiment can be used to explain how an investor holding Gilead can time the market purely based on public headlines and social activities around Gilead Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Gilead Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Gilead Sciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Gilead Sciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Gilead Sciences.

Gilead Sciences Implied Volatility

    
  24.93  
Gilead Sciences' implied volatility exposes the market's sentiment of Gilead Sciences stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Gilead Sciences' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Gilead Sciences stock will not fluctuate a lot when Gilead Sciences' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Gilead Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Gilead Sciences' short interest history, or implied volatility extrapolated from Gilead Sciences options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Global Correlations
Find global opportunities by holding instruments from different markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.